S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
DIS   96.97 (+2.16%)
Log in

NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, Forecast & News

$84.52
-0.48 (-0.56 %)
(As of 04/2/2020 04:00 PM ET)
Today's Range
$82.57
Now: $84.52
$87.67
50-Day Range
$72.48
MA: $100.10
$129.96
52-Week Range
$67.98
Now: $84.52
$196.00
Volume351,140 shs
Average Volume618,279 shs
Market Capitalization$2.61 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.99
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More
GW Pharmaceuticals PLC- logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$311.33 million
Cash Flow$0.01 per share
Book Value$23.48 per share

Profitability

Net Income$-9,020,000.00

Miscellaneous

Employees791
Market Cap$2.61 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.


GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions

How has GW Pharmaceuticals PLC-'s stock been impacted by COVID-19 (Coronavirus)?

GW Pharmaceuticals PLC-'s stock was trading at $86.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GWPH shares have decreased by 2.7% and is now trading at $84.52. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GW Pharmaceuticals PLC-?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GW Pharmaceuticals PLC-.

When is GW Pharmaceuticals PLC-'s next earnings date?

GW Pharmaceuticals PLC- is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for GW Pharmaceuticals PLC-.

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) released its earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.52) by $0.32. The biopharmaceutical company earned $109.10 million during the quarter, compared to analysts' expectations of $80.92 million. GW Pharmaceuticals PLC- had a negative return on equity of 16.12% and a negative net margin of 2.90%. GW Pharmaceuticals PLC-'s quarterly revenue was up 1528.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.20) EPS. View GW Pharmaceuticals PLC-'s earnings history.

What price target have analysts set for GWPH?

13 Wall Street analysts have issued 1-year price targets for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $134.00 to $260.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $198.42 in the next twelve months. This suggests a possible upside of 134.8% from the stock's current price. View analysts' price targets for GW Pharmaceuticals PLC-.

Has GW Pharmaceuticals PLC- been receiving favorable news coverage?

News headlines about GWPH stock have been trending very negative on Thursday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. GW Pharmaceuticals PLC- earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutGW Pharmaceuticals PLC-.

Are investors shorting GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- saw a decrease in short interest in February. As of February 28th, there was short interest totaling 5,250,000 shares, a decrease of 6.9% from the February 13th total of 5,640,000 shares. Based on an average trading volume of 609,800 shares, the days-to-cover ratio is presently 8.6 days. Currently, 17.1% of the shares of the company are short sold. View GW Pharmaceuticals PLC-'s Current Options Chain.

Who are some of GW Pharmaceuticals PLC-'s key competitors?

What other stocks do shareholders of GW Pharmaceuticals PLC- own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Aurora Cannabis (ACB), Cronos Group (CRON), Tesla (TSLA), Zynerba Pharmaceuticals (ZYNE) and Intel (INTC).

Who are GW Pharmaceuticals PLC-'s key executives?

GW Pharmaceuticals PLC-'s management team includes the following people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 48)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)
  • Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61)

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

How do I buy shares of GW Pharmaceuticals PLC-?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GW Pharmaceuticals PLC-'s stock price today?

One share of GWPH stock can currently be purchased for approximately $84.52.

How big of a company is GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- has a market capitalization of $2.61 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe. View additional information about GW Pharmaceuticals PLC-.

What is GW Pharmaceuticals PLC-'s official website?

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/.

How can I contact GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]


MarketBeat Community Rating for GW Pharmaceuticals PLC- (NASDAQ GWPH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  793 (Vote Outperform)
Underperform Votes:  524 (Vote Underperform)
Total Votes:  1,317
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel